EP0069715B1 - Powder inhalator - Google Patents
Powder inhalator Download PDFInfo
- Publication number
- EP0069715B1 EP0069715B1 EP82850129A EP82850129A EP0069715B1 EP 0069715 B1 EP0069715 B1 EP 0069715B1 EP 82850129 A EP82850129 A EP 82850129A EP 82850129 A EP82850129 A EP 82850129A EP 0069715 B1 EP0069715 B1 EP 0069715B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- active compound
- membrane
- perforations
- dosage
- perforated membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000843 powder Substances 0.000 title claims abstract description 18
- 239000012528 membrane Substances 0.000 claims abstract description 76
- 150000001875 compounds Chemical class 0.000 claims abstract description 75
- 239000007787 solid Substances 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 description 9
- 210000002345 respiratory system Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Definitions
- the present invention relates to a new dosage inhalator, intended to be activated using the air flow generated at inhalation and intended to be used for inhalation of pharmacologically active compound in solid, micronized form.
- dosage inhalators intended for local administration of drugs to the respiratory tract and to the lungs. Since mostly very potent drugs are to be administered, the dose accuracy must be great.
- the dosage of active compound that is to be administered may be as small as 0.1 mg. It is also necessary that the particles that leave the dosage inhalator have a suitable size distribution, since too big particles tend to be deposited in the mouth.
- powder inhalators are available on the market. They represent a complement to pressurized aerosols, where the drug is dissolved or suspended in a liquid propellant mixture.
- the powder inhalators have the advantage that they always deliver the active compound when the patient inhales, as the particle cloud is generated by the air flow obtained at inhalation. Thereby the problem of coordinating the activation of a dosage with the inhalation in orderto bring the active compound to the respiratory tract and to the lungs is solved.
- An example of powder inhalators which are available on the market is Spinhaler O. In Spin- haler& the active compound is used in micronized form, contained in a hard gelatine capsule which is perforated before use. The hard gelatine capsule is placed in a tube in a device which is brought to rotation by the air flow generated at inhalation, whereby the micronized compound is moved into the air stream and is brought via the airflow to the respiratory tract and lungs of the patient.
- the British patent publication GB-A-2 041 763 discloses an inhalator, which is activated by the air flow generated at inhalation and intended for free flowing pulverulent medicinal substances, wherein the active substance is measured in dosing holes and then poured onto a dispensing disc wherefrom the active substance is inhaled by the patient.
- US patent specification US-A-2 587 215 discloses an inhalator utilizing cavities in a disc as means for transporting a measured amount of free flowing powder to be inhalated from a storage space to a position from where it is inhaled by the air flow generated at inhalation.
- the present invention relates to a dosage inhalator, a so called “powder inhalator", which is activated by the air flow generated at inhalation, and which makes it possible to dispense solid active compound in micronized form, in a suitable size distribution, in an amount from 0.1 mg without need for any diluting agent.
- the dosage inhalator can be constructed for administering active compound in an amount up to 5 mg. It can also, with suitable construction of the dosing unit be used for administering active compound in an amount of 5-50 mg.
- the present invention relates to a powder inhalator which is activated by the airflow generated at inhalation and which is intended for inhalation of a pre-determined amount of solid pharmacologically active compound in micronized form, said inhalator comprising a nozzle, an air conduit connected to said nozzle for passage of the air to be inhaled, a dosing unit comprising a storage chamber for the active compound and a displaceable element for dispensing said compound from the storage chamber into the air conduit and a manoeuvring unit for displacing said element in relation to the storage chamber
- the powder inhalator being characterized in that the dispensing element is a perforated membrane, that the dosing unit comprises also a holderforthesaid perforated membrane, means for introducing and metering active compound into the perforations in the perforated membrane, and a plate arranged adjacent the membrane to prevent active compound from passing through the perforations in the membrane when active compound is introduced into the perforations, the said membrane being displaceably
- the dosing means in combination with the storage chamber for the active compound represent the essential new elements in the powder inhalator according to the invention.
- the dosage inhalator comprises a maneuvering unit 1 which is used for feeding dosages of the active compound, a nozzle 2 which may be provided with rotating means 3 intended for disrupting such aggregate particles of the active compound which might have been formed, a dosing unit 10 for measuring the intended dosage of the active compound and a storage chamber 5 for solid micronized active compound.
- the dosage inhalator also comprises an air conduit 6 intended for passage of the air to be inhaled.
- the nozzle 2 can be provided with rotating means 3 intended for disrupting such aggregate particles of the active compound which might have been formed. The disintegration of possible particle aggregates is facilitated by air inlets 7 arranged at the side of the nozzle 2.
- the dosing unit 10 comprises a storage chamber 5 for the active compound a perforated membrane 4, a holder 9 for the perforated membrane, and dosing means 8, schematically shown in Figure 1, for introducing the active compound into the perforations in the perforated membrane 4.
- the dosing unit 10 and the perforated membrane 4 are displaceably arranged in relation to one another between a first position where active compound by the dosing means 8 is introduced into the perforations in part of the area of the perforated membrane 4, and a second position where the said part area of the loaded membrane 4 has been inserted across the air conduit 6 in the dosage inhalator. In said first position of the membrane 4, the active compound is brought from the storage chamber 5 into the perforations in the membrane 4.
- the active compound contained in the perforations will be entrained at inhalation and be brought through the nozzle 2 tq the respiratory tract and the lungs of the patient.
- the perforated membrane 4 is displaceably arranged in relation to the storage chamber 5.
- the dosing unit 10 comprises a perforated membrane 4 which can be rotated and which is intended to be loaded with solid active compound in micronized form.
- elastic spring-loaded scrapers 15 are arranged in the storage chamber 5 to introduce active compound into the perforations in the perforated membrane 4.
- the perforations in the perforated membrane 4 are in the form of truncated cones with their large opening directed to the nozzle.
- the scrapers 15 are suitably manufactured in an elastic material, for example rubber or plastic.
- the scrapers are suitably arranged so that they, when the active compound is introduced into the perforations in the membrane 4, touch the surface of the membrane at an angle which is less than 90°.
- the means for introducing active compound into the perforations in the membrane are arranged in this manner, the additional advantage is obtained that possible aggregates of active compound are disintegrated before administration.
- the scrapers 15 are suitably arranged so that they press against the surface of the membrane 4. That is achieved as shown in Figure 1 by having the scrapers 15 loaded by a spring 12.
- the spring 12 is arranged in the storage chamber 5 as is shown in Figure 1.
- a spring can be arranged so that the membrane 4 is pressed against the scrapers 15.
- the spring may in such case be arranged outside the storage chamber 5, suitably mounted in the maneuvering unit 1. Further variations are possible.
- the essential element is that the scrapers 15 press against the membrane 4 in such a way that active compound is introduced into the perforations in the membrane 4 when the maneuvering unit is operated. See Figure 2 and Figure 3.
- a plate 13 is arranged which prevents active compound from passing through the perforations in the membrane 4. See Figure 1.
- the plate 13 will comprise the bottom of the perforations.
- the air conduit 6 passes through the maneuvering unit 1. At inhalation through the nozzle 2 the air flow will pass partly through the air inlets 7 arranged at the side of the nozzle 2, partly through the air conduit 6.
- the air in the air conduit 6 passes through its opening 14 in the maneuvering unit 1.
- a perforated plate 18 is arranged as a filter in the opening 14 in order to prevent undesired particles of larger size from entering the air conduit 6.
- the perforated membrane 4 in the dosing unit 10 can be made, as is illustrated in Figure 1 and in Figure 3, as a horizontal membrane. But also other embodiments are possible, for example a membrane in the form of a drum where the active compound is filled into the perforations from a storage chamber which can be arranged outside the drum or inside the drum.
- the membrane When a membrane in the form of a horizontal plane is used, as illustrated in Figure 1, the membrane can be mounted so that it can be moved by rotating it, whereby the other parts of the dosage inhalator are fixed relative to one another.
- the said perforations in the membrane are suitably formed as truncated cones, see Figure 3, with the wider opening directed towards the nozzle.
- Perforations in the form of truncated cones facilitate the emptying of the perforations in that the active compound is released more easily.
- the storage chamber 5 is arranged between the membrane and the nozzle, also the filling of the perforations is facilitated if the perforations are designed as is shown in Figure 3.
- the perforations in the perforated membranes can be of arbitrary design. They can be circular, square, elliptic, rectangular or have other geometrical form.
- the area of the perforations in the membrane can be a large or a small part of the membrane area, for example from 1 to 95%, whereby the term "membrane area" refers to that part of the area of the membrane which is inserted across the air conduit.
- the number of perforations in the membrane area can vary depending on factors such as the amount of active substance that is to be administered per dosage, the physical properties of the active substance, etc. In a preferred embodiment the perforations have conical shape.
- the perforated membrane can be manufactured in any suitable material, for example metal or plastic.
- the size of the dosage of active - compound which is to be administered is determined by the size of the perforations in the membrane, the thickness of the membrane, the number of perforations in the membrane and by the size of the air conduit. A single perforation may be sufficient for dispensing a given dose of the active compound.
- the accuracy of the dosage will mainly depend on the accuracy in the manufacturing of the membrane.
- Examples of perforated membranes that can be used are the metal nets which are manufactured by Veco Beheer B.V., Eerbeek, The Netherlands. These nets can be obtained with various sizes of the perforations. They can be formed in desired manner, for example in drum form or they can be used in the form of horizontal, plane membranes. Also woven nets of metal, fiber or of other materials can be used. The important factor is the dosage accuracy that can be obtained.
- the maneuvering unit 1 is in the embodiment shown in Figure 1 arranged adjacent to the dosing unit 10.
- the maneuvering unit can be made in the form of a dented ring.
- Spring-loaded pins 11, see Figure 1 are used to provide distinct positions for the perforated membrane when it is advanced by operating the maneuvering unit 1.
- the maneuvering unit can be arranged also otherwise, for example by arranging it to operate directly on the perforated membrane.
- the storage chamber is in a preferred embodiment arranged between the perforated membrane and the nozzle. See Figure 1.
- the storage chamber can be arranged to accommodate a varying amount of the active compound.
- the storage chamber In a dosage inhalator where the storage chamber is not made for refilling of active compound it can contain an amount of active compound corresponding for example up to about 200 dosage units.
- a device In a dosage inhalator where the storage chamber is intended for refilling a device is required which can be arranged on the top or on the sides of the storage chamber.
- a screw or plug 16 can be arranged in the storage chamber 5 as is shown in Figure 1.
- the air conduit 6 can have an area of 25-350 mm 2 .
- the air conduit can be circular or have other geometrical form. If it is circular, the diameter may be from 3 to 10 mm.
- terbutaline and budesonids are especially useful.
- the active compound can be administered in micronized form without additional ingredients or in pharmaceutically modified micronized form in order to obtain improved flow properties.
- the micronized particles may be covered with a film functioning for example by masking bitter taste of the active compound, or by providing slow release of the active compound in the respiratory tract.
- the present invention relates to the use in powder inhalator of a perforated membrane as metering and holding means for solid micronized active compound.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Disintegrating Or Milling (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Filtering Of Dispersed Particles In Gases (AREA)
- Nozzles (AREA)
- Steroid Compounds (AREA)
Abstract
Description
- The present invention relates to a new dosage inhalator, intended to be activated using the air flow generated at inhalation and intended to be used for inhalation of pharmacologically active compound in solid, micronized form.
- Special requirements are made with regard to dosage inhalators intended for local administration of drugs to the respiratory tract and to the lungs. Since mostly very potent drugs are to be administered, the dose accuracy must be great. The dosage of active compound that is to be administered may be as small as 0.1 mg. It is also necessary that the particles that leave the dosage inhalator have a suitable size distribution, since too big particles tend to be deposited in the mouth.
- Several systems are available for local administration of drugs to the respiratory tract and to the lungs. Among these systems may be mentioned nebulizing devices, pressurized aerosols, pump inhalators, and inhalators which are activated by the air flow generated at inhalation, herebelow denoted "powder inhalators".
- Several types of powder inhalators are available on the market. They represent a complement to pressurized aerosols, where the drug is dissolved or suspended in a liquid propellant mixture. The powder inhalators have the advantage that they always deliver the active compound when the patient inhales, as the particle cloud is generated by the air flow obtained at inhalation. Thereby the problem of coordinating the activation of a dosage with the inhalation in orderto bring the active compound to the respiratory tract and to the lungs is solved. An example of powder inhalators which are available on the market is SpinhalerO. In Spin- haler& the active compound is used in micronized form, contained in a hard gelatine capsule which is perforated before use. The hard gelatine capsule is placed in a tube in a device which is brought to rotation by the air flow generated at inhalation, whereby the micronized compound is moved into the air stream and is brought via the airflow to the respiratory tract and lungs of the patient.
- The British patent publication GB-A-2 041 763 discloses an inhalator, which is activated by the air flow generated at inhalation and intended for free flowing pulverulent medicinal substances, wherein the active substance is measured in dosing holes and then poured onto a dispensing disc wherefrom the active substance is inhaled by the patient. ,
- The US patent specification US-A-2 587 215 discloses an inhalator utilizing cavities in a disc as means for transporting a measured amount of free flowing powder to be inhalated from a storage space to a position from where it is inhaled by the air flow generated at inhalation.
- However, the previously known powder inhalators have disadvantages:
- 1) they cannot be used for accurate and reproducible dispensing of micronized active compound in amounts below 15-20 mg, and they are therefor useful only for less potent active compounds or for highly potent active compounds in combination with a diluting agent, usually lactose;
- 2) they are cumbersome to load and to make clean;
- 3) usually several inhalations are required to empty a capsule containing a unit dose;
- 4) they are difficult to handle for patients with reduced breathing capacity or with reduced capability in the use of their hands;
- 5) lactose, the diluting agent, is very disturbing at inhalation and may cause increased frequence of caries.
- There is a need for an effective powder inhalator which is activated by the air flow generated at inhalation, which is easy to handle for the patient, which allows dispensation of active compound in an amount down to 0.1 mg without need to include any diluting agent, and which gives a suitable size distribution for the particles which are administered.
- The present invention relates to a dosage inhalator, a so called "powder inhalator", which is activated by the air flow generated at inhalation, and which makes it possible to dispense solid active compound in micronized form, in a suitable size distribution, in an amount from 0.1 mg without need for any diluting agent. The dosage inhalator can be constructed for administering active compound in an amount up to 5 mg. It can also, with suitable construction of the dosing unit be used for administering active compound in an amount of 5-50 mg.
- The present invention relates to a powder inhalator which is activated by the airflow generated at inhalation and which is intended for inhalation of a pre-determined amount of solid pharmacologically active compound in micronized form, said inhalator comprising a nozzle, an air conduit connected to said nozzle for passage of the air to be inhaled, a dosing unit comprising a storage chamber for the active compound and a displaceable element for dispensing said compound from the storage chamber into the air conduit and a manoeuvring unit for displacing said element in relation to the storage chamber said powder inhalator being characterized in that the dispensing element is a perforated membrane, that the dosing unit comprises also a holderforthesaid perforated membrane, means for introducing and metering active compound into the perforations in the perforated membrane, and a plate arranged adjacent the membrane to prevent active compound from passing through the perforations in the membrane when active compound is introduced into the perforations, the said membrane being displaceably arranged in relation to said means for introducing the compound so that in a first position solid active compound in micronized form is introduced into the perforations in part of the area of the membrane and in a second position the said part of the area of the membrane including perforations holding the predetermined amount of active compound is inserted across the air conduit for the air to be inhaled.
- The dosing means in combination with the storage chamber for the active compound represent the essential new elements in the powder inhalator according to the invention.
- One embodiment of the dosage inhalator according to the invention is now described more in detail with reference to Figures 1, 2, and 3.
- Figure 1 is a sectional view through the dosage inhalator according to the invention.
- Figure 2 shows scrapers in the storage chamber, which scrapers are used to introduce active compound into the perforations in the perforated membrane.
- Figure 3 shows how the active compound is fed from the storage unit into the perforations in the perforated membrane using the said scrapers.
- The dosage inhalator comprises a maneuvering unit 1 which is used for feeding dosages of the active compound, a
nozzle 2 which may be provided with rotating means 3 intended for disrupting such aggregate particles of the active compound which might have been formed, adosing unit 10 for measuring the intended dosage of the active compound and astorage chamber 5 for solid micronized active compound. - The dosage inhalator also comprises an
air conduit 6 intended for passage of the air to be inhaled. Thenozzle 2 can be provided with rotating means 3 intended for disrupting such aggregate particles of the active compound which might have been formed. The disintegration of possible particle aggregates is facilitated byair inlets 7 arranged at the side of thenozzle 2. - The
dosing unit 10 comprises astorage chamber 5 for the active compound aperforated membrane 4, a holder 9 for the perforated membrane, and dosing means 8, schematically shown in Figure 1, for introducing the active compound into the perforations in theperforated membrane 4. Thedosing unit 10 and theperforated membrane 4 are displaceably arranged in relation to one another between a first position where active compound by the dosing means 8 is introduced into the perforations in part of the area of theperforated membrane 4, and a second position where the said part area of the loadedmembrane 4 has been inserted across theair conduit 6 in the dosage inhalator. In said first position of themembrane 4, the active compound is brought from thestorage chamber 5 into the perforations in themembrane 4. When a part area of themembrane 4 containing such perforations filled with active compound thereafter is inserted across theair conduit 6, the active compound contained in the perforations will be entrained at inhalation and be brought through thenozzle 2 tq the respiratory tract and the lungs of the patient. - The introduction of active compound into the perforations in the
perforated membrane 4 is in the described embodiment made withmechanical means 8 consisting of elastic, spring-loadedscrapers 15, mounted in aholder 17 in thestorage chamber 5. See Figures 2 and 3. - In a preferred embodiment, the
perforated membrane 4 is displaceably arranged in relation to thestorage chamber 5. - In another preferred embodiment, the
dosing unit 10 comprises aperforated membrane 4 which can be rotated and which is intended to be loaded with solid active compound in micronized form. - In a further preferred embodiment, elastic spring-loaded
scrapers 15 are arranged in thestorage chamber 5 to introduce active compound into the perforations in theperforated membrane 4. - In another preferred embodiment, the perforations in the
perforated membrane 4 are in the form of truncated cones with their large opening directed to the nozzle. - The
scrapers 15 are suitably manufactured in an elastic material, for example rubber or plastic. The scrapers are suitably arranged so that they, when the active compound is introduced into the perforations in themembrane 4, touch the surface of the membrane at an angle which is less than 90°. When the means for introducing active compound into the perforations in the membrane are arranged in this manner, the additional advantage is obtained that possible aggregates of active compound are disintegrated before administration. - The
scrapers 15 are suitably arranged so that they press against the surface of themembrane 4. That is achieved as shown in Figure 1 by having thescrapers 15 loaded by aspring 12. Thespring 12 is arranged in thestorage chamber 5 as is shown in Figure 1. - Alternatively, a spring can be arranged so that the
membrane 4 is pressed against thescrapers 15. The spring may in such case be arranged outside thestorage chamber 5, suitably mounted in the maneuvering unit 1. Further variations are possible. The essential element is that thescrapers 15 press against themembrane 4 in such a way that active compound is introduced into the perforations in themembrane 4 when the maneuvering unit is operated. See Figure 2 and Figure 3. - In the maneuvering unit 1, immediately adjacent to the
membrane 4, aplate 13 is arranged which prevents active compound from passing through the perforations in themembrane 4. See Figure 1. Thus, theplate 13 will comprise the bottom of the perforations. - The
air conduit 6 passes through the maneuvering unit 1. At inhalation through thenozzle 2 the air flow will pass partly through theair inlets 7 arranged at the side of thenozzle 2, partly through theair conduit 6. The air in theair conduit 6 passes through itsopening 14 in the maneuvering unit 1. In the embodiment shown in Figure 1, aperforated plate 18 is arranged as a filter in theopening 14 in order to prevent undesired particles of larger size from entering theair conduit 6. - The
perforated membrane 4 in thedosing unit 10 can be made, as is illustrated in Figure 1 and in Figure 3, as a horizontal membrane. But also other embodiments are possible, for example a membrane in the form of a drum where the active compound is filled into the perforations from a storage chamber which can be arranged outside the drum or inside the drum. - When a membrane in the form of a horizontal plane is used, as illustrated in Figure 1, the membrane can be mounted so that it can be moved by rotating it, whereby the other parts of the dosage inhalator are fixed relative to one another.
- In order to make sure that the amount of active compound that has been filled into the perforations which are inserted in the
air conduit 6 is released from the perforations and entrained at inhalation, the said perforations in the membrane are suitably formed as truncated cones, see Figure 3, with the wider opening directed towards the nozzle. Perforations in the form of truncated cones facilitate the emptying of the perforations in that the active compound is released more easily. Moreover, when thestorage chamber 5 is arranged between the membrane and the nozzle, also the filling of the perforations is facilitated if the perforations are designed as is shown in Figure 3. - The perforations in the perforated membranes can be of arbitrary design. They can be circular, square, elliptic, rectangular or have other geometrical form. The area of the perforations in the membrane can be a large or a small part of the membrane area, for example from 1 to 95%, whereby the term "membrane area" refers to that part of the area of the membrane which is inserted across the air conduit. The number of perforations in the membrane area can vary depending on factors such as the amount of active substance that is to be administered per dosage, the physical properties of the active substance, etc. In a preferred embodiment the perforations have conical shape.
- The perforated membrane can be manufactured in any suitable material, for example metal or plastic. The size of the dosage of active - compound which is to be administered is determined by the size of the perforations in the membrane, the thickness of the membrane, the number of perforations in the membrane and by the size of the air conduit. A single perforation may be sufficient for dispensing a given dose of the active compound. The accuracy of the dosage will mainly depend on the accuracy in the manufacturing of the membrane. Examples of perforated membranes that can be used are the metal nets which are manufactured by Veco Beheer B.V., Eerbeek, The Netherlands. These nets can be obtained with various sizes of the perforations. They can be formed in desired manner, for example in drum form or they can be used in the form of horizontal, plane membranes. Also woven nets of metal, fiber or of other materials can be used. The important factor is the dosage accuracy that can be obtained.
- The maneuvering unit 1 is in the embodiment shown in Figure 1 arranged adjacent to the
dosing unit 10. The maneuvering unit can be made in the form of a dented ring. Spring-loadedpins 11, see Figure 1, are used to provide distinct positions for the perforated membrane when it is advanced by operating the maneuvering unit 1. The maneuvering unit can be arranged also otherwise, for example by arranging it to operate directly on the perforated membrane. - The storage chamber is in a preferred embodiment arranged between the perforated membrane and the nozzle. See Figure 1.
- The storage chamber can be arranged to accommodate a varying amount of the active compound. In a dosage inhalator where the storage chamber is not made for refilling of active compound it can contain an amount of active compound corresponding for example up to about 200 dosage units. In a dosage inhalator where the storage chamber is intended for refilling a device is required which can be arranged on the top or on the sides of the storage chamber. For example, a screw or plug 16 can be arranged in the
storage chamber 5 as is shown in Figure 1. - The
air conduit 6 can have an area of 25-350 mm2. The air conduit can be circular or have other geometrical form. If it is circular, the diameter may be from 3 to 10 mm. - Among compound groups and specific compounds which are suitable for administering with a powder inhalator according to the present invention can be mentioned
- - betareceptorstimulating agents such as adrenaline, isoprenaline, orciprenaline, salbutamol and terbutaline,
- - steroids for inhalation such as budesonide,
- -substances intended for nasal administration.
- Especially useful are terbutaline and budesonids.
- The active compound can be administered in micronized form without additional ingredients or in pharmaceutically modified micronized form in order to obtain improved flow properties. The micronized particles may be covered with a film functioning for example by masking bitter taste of the active compound, or by providing slow release of the active compound in the respiratory tract.
- In an additional aspect, the present invention relates to the use in powder inhalator of a perforated membrane as metering and holding means for solid micronized active compound.
Claims (9)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT82850129T ATE23272T1 (en) | 1981-07-08 | 1982-06-10 | POWDER INHALER. |
MYPI87002747A MY100090A (en) | 1981-07-08 | 1987-10-01 | Powder inhalator |
KE3890A KE3890A (en) | 1981-07-08 | 1989-06-21 | Powder inhalator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8104239 | 1981-07-08 | ||
SE8104239 | 1981-07-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0069715A1 EP0069715A1 (en) | 1983-01-12 |
EP0069715B1 true EP0069715B1 (en) | 1986-11-05 |
Family
ID=20344220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP82850129A Expired EP0069715B1 (en) | 1981-07-08 | 1982-06-10 | Powder inhalator |
Country Status (30)
Country | Link |
---|---|
US (1) | US4524769A (en) |
EP (1) | EP0069715B1 (en) |
JP (1) | JPS5819269A (en) |
KR (1) | KR880001811B1 (en) |
AT (1) | ATE23272T1 (en) |
AU (1) | AU559297B2 (en) |
CA (1) | CA1178151A (en) |
CY (1) | CY1492A (en) |
DE (1) | DE3274065D1 (en) |
DK (1) | DK159052C (en) |
EG (1) | EG16516A (en) |
ES (1) | ES276079Y (en) |
FI (1) | FI77375C (en) |
GR (1) | GR76522B (en) |
HK (1) | HK64389A (en) |
HU (1) | HU189154B (en) |
IE (1) | IE53933B1 (en) |
IL (1) | IL66053A (en) |
IN (1) | IN158972B (en) |
IS (1) | IS1268B6 (en) |
KE (1) | KE3890A (en) |
MY (1) | MY100090A (en) |
NO (1) | NO154294C (en) |
NZ (1) | NZ201154A (en) |
PH (1) | PH22387A (en) |
PL (1) | PL132252B1 (en) |
PT (1) | PT75211B (en) |
SG (1) | SG37089G (en) |
YU (1) | YU45115B (en) |
ZA (1) | ZA824264B (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4319514A1 (en) * | 1993-06-14 | 1994-12-15 | Asta Medica Ag | Bulk inhaler |
US5983893A (en) * | 1994-12-21 | 1999-11-16 | Astra Aktiebolag | Inhalation device |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
US7125566B2 (en) | 1999-12-21 | 2006-10-24 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7718609B2 (en) | 2006-04-12 | 2010-05-18 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7964615B2 (en) | 2005-05-20 | 2011-06-21 | Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor |
US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US8513279B2 (en) | 1999-07-14 | 2013-08-20 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US8933023B2 (en) | 2004-03-12 | 2015-01-13 | Biodel Inc. | Rapid acting injectable insulin compositions |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9254262B2 (en) | 2008-03-13 | 2016-02-09 | Almirall, S.A. | Dosage and formulation |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
Families Citing this family (331)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE438261B (en) * | 1981-07-08 | 1985-04-15 | Draco Ab | USE IN A DOSHALATOR OF A PERFORED MEMBRANE |
SE448277B (en) * | 1985-04-12 | 1987-02-09 | Draco Ab | INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS |
SE453566B (en) * | 1986-03-07 | 1988-02-15 | Draco Ab | POWDER INHALATOR DEVICE |
US4739754A (en) * | 1986-05-06 | 1988-04-26 | Shaner William T | Suction resistant inhalator |
US4929329A (en) * | 1987-04-27 | 1990-05-29 | Eg&G, Inc. | Electrophoresis cassette system with apparatus and method for filling same |
GB8909891D0 (en) * | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
AU643435B2 (en) * | 1989-04-28 | 1993-11-18 | Riker Laboratories, Inc. | Dry powder inhalation device |
US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
IT1237118B (en) * | 1989-10-27 | 1993-05-18 | Miat Spa | MULTI-DOSE INHALER FOR POWDER DRUGS. |
US5192548A (en) * | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
GB9015522D0 (en) * | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
DE69121105T2 (en) * | 1990-09-12 | 1996-12-12 | Hans Bisgaard | INHALING DEVICE |
GB9021433D0 (en) * | 1990-10-02 | 1990-11-14 | Atomic Energy Authority Uk | Power inhaler |
FR2667509B1 (en) * | 1990-10-04 | 1995-08-25 | Valois | POWDER INHALER, DEVICE FOR PACKAGING POWDER MICRODOSES IN THE FORM OF BANDS SUITABLE FOR USE IN A POWDER INHALER, AND METHOD FOR MANUFACTURING SUCH BANDS. |
US5304125A (en) * | 1990-10-05 | 1994-04-19 | The University Of North Carolina | Apparatus for administering solid particulate aerosols to the lungs |
US5450336A (en) * | 1991-03-05 | 1995-09-12 | Aradigm Corporation | Method for correcting the drift offset of a transducer |
US5392768A (en) * | 1991-03-05 | 1995-02-28 | Aradigm | Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval |
JP3532204B2 (en) * | 1991-03-05 | 2004-05-31 | アラダイム コーポレーション | Method and apparatus for correcting drift offset of a flow sensor pressure sensor |
US5469750A (en) * | 1991-03-05 | 1995-11-28 | Aradigm Corporation | Method and apparatus for sensing flow in two directions and automatic calibration thereof |
US5404871A (en) * | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5295479A (en) * | 1991-04-15 | 1994-03-22 | Leiras Oy | Device intended for measuring a dose of powdered medicament for inhalation |
US5243970A (en) * | 1991-04-15 | 1993-09-14 | Schering Corporation | Dosing device for administering metered amounts of powdered medicaments to patients |
US5327883A (en) * | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
US5492112A (en) * | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
FR2676929B1 (en) * | 1991-05-30 | 1994-02-11 | Aerosols Bouchage Ste Fse | POWDER INHALER. |
CN1050764C (en) * | 1991-06-26 | 2000-03-29 | 先灵公司 | Inhalation device for powdered medicaments |
US5161524A (en) * | 1991-08-02 | 1992-11-10 | Glaxo Inc. | Dosage inhalator with air flow velocity regulating means |
DK0601071T3 (en) * | 1991-08-26 | 2000-04-03 | Minnesota Mining & Mfg | powder dispenser |
US6029661A (en) * | 1991-08-26 | 2000-02-29 | 3M Innovative Properties Company | Powder dispenser |
DE4208880A1 (en) * | 1992-03-19 | 1993-09-23 | Boehringer Ingelheim Kg | SEPARATOR FOR POWDER INHALATORS |
EP0632734B1 (en) * | 1992-03-25 | 1998-06-10 | Tebro S.A. | Powder jet dispenser for medicament inhalation therapies |
SE9201411D0 (en) * | 1992-05-05 | 1992-05-05 | Astra Ab | DOSAGE INHALATOR WITH INDICATING / INTERUPTING MEANS |
DE9307115U1 (en) * | 1992-05-29 | 1993-09-02 | GGU Gesellschaft für Gesundheits- und Umweltforschung mbH & Co. Vertriebs KG, 65933 Frankfurt | Device for producing inhalable active substances |
US5394868A (en) * | 1992-06-25 | 1995-03-07 | Schering Corporation | Inhalation device for powdered medicaments |
HU217917B (en) * | 1992-10-19 | 2000-05-28 | Dura Pharmaceuticals Inc. | Inhaler for inhaling dry powders |
WO1994011044A2 (en) | 1992-11-12 | 1994-05-26 | Minnesota Mining And Manufacturing Company | Powder inhaler |
DE4239402A1 (en) * | 1992-11-24 | 1994-05-26 | Bayer Ag | Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion |
US6250300B1 (en) | 1992-12-11 | 2001-06-26 | Ab Astra | System for dispensing pharmaceutically active compounds |
SE9203743D0 (en) * | 1992-12-11 | 1992-12-11 | Astra Ab | EFFICIENT USE |
EP0674533B1 (en) * | 1992-12-18 | 1999-03-10 | Schering Corporation | Inhaler for powdered medications |
FR2700279B1 (en) * | 1993-01-14 | 1995-03-17 | Valois | Portable device for projecting doses of a fluid substance using a stream of compressed air. |
KR960701672A (en) * | 1993-03-03 | 1996-03-28 | 윌리엄 피. 알트만 | DRY POWDER INHALATOR MEDICAMENT CARRIER |
GB9306703D0 (en) * | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
US5747445A (en) * | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
IS1796B (en) * | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
US20010003739A1 (en) * | 1993-06-24 | 2001-06-14 | Astrazeneca Ab | Systemic administration of a therapeutic preparation |
US6794357B1 (en) | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
US5830853A (en) * | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
DE4400084C2 (en) * | 1994-01-04 | 2001-08-02 | Softec Gmbh & Co Kg | Device for administering medication in solid form finely distributed in an air stream |
PT101450B (en) * | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | NEW INHALATION DEVICE |
AU124387S (en) * | 1994-03-25 | 1995-08-11 | Astra Ab | Training device for an inhaler |
US6102036A (en) * | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
DE4415462C1 (en) * | 1994-05-03 | 1995-08-31 | Transcoject Marketing Gmbh | Inhaler for powdered medicine etc. |
US6165976A (en) | 1994-06-23 | 2000-12-26 | Astra Aktiebolag | Therapeutic preparation for inhalation |
US5522385A (en) * | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5980949A (en) * | 1994-10-03 | 1999-11-09 | Astra Aktiebolag | Formulation for inhalation |
US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
US5647347A (en) * | 1994-10-21 | 1997-07-15 | Glaxo Wellcome Inc. | Medicament carrier for dry powder inhalator |
JPH10511090A (en) * | 1994-12-22 | 1998-10-27 | アストラ・アクチエボラーグ | Parathyroid hormone, PTH-containing therapeutic preparation for inhalation |
SK81197A3 (en) | 1994-12-22 | 1997-11-05 | Astra Ab | Aerosol drug formulations, method for production thereof and its use |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
DE19500764C2 (en) * | 1995-01-13 | 2001-09-27 | Sofotec Gmbh & Co Kg | Device for administering medication in solid form, finely distributed in an air stream |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
DE19518810A1 (en) * | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal applicator |
US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
JP3317823B2 (en) * | 1995-08-11 | 2002-08-26 | 株式会社ユニシアジェックス | Dosing device |
SE9503344D0 (en) | 1995-09-27 | 1995-09-27 | Astra Ab | Inhalation device |
US5797392C1 (en) * | 1996-01-22 | 2001-01-09 | Direct Haler As | Inhaler |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
GB9626263D0 (en) | 1996-12-18 | 1997-02-05 | Innovata Biomed Ltd | Powder inhaler |
SE9700135D0 (en) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
SE9700133D0 (en) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
TW469832U (en) | 1997-03-14 | 2001-12-21 | Astra Ab | Inhalation device |
SE9700937D0 (en) | 1997-03-14 | 1997-03-14 | Astra Ab | Powder inhales I |
SE9700936D0 (en) | 1997-03-14 | 1997-03-14 | Astra Ab | Inhalation device |
US6006747A (en) | 1997-03-20 | 1999-12-28 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
CA2212430A1 (en) | 1997-08-07 | 1999-02-07 | George Volgyesi | Inhalation device |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6237591B1 (en) | 1998-11-02 | 2001-05-29 | Dura Pharmaceuticals, Inc. | Turbine dry powder inhaler |
US6260549B1 (en) * | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
DE19831525A1 (en) * | 1998-07-14 | 2000-01-20 | Pfeiffer Erich Gmbh & Co Kg | Media Donor |
US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
GB9902493D0 (en) | 1999-02-05 | 1999-03-24 | Glaxo Group Ltd | Inhalation device |
GB9905538D0 (en) | 1999-03-10 | 1999-05-05 | Glaxo Group Ltd | A device |
US6223744B1 (en) | 1999-03-16 | 2001-05-01 | Multi-Vet Ltd. | Wearable aerosol delivery apparatus |
CA2366922C (en) | 1999-04-21 | 2008-07-22 | 1355540 Ontario Inc. | Formulations for detecting asthma |
WO2000074754A2 (en) * | 1999-06-05 | 2000-12-14 | Innovata Biomed Limited | Delivery system |
DK1196430T3 (en) | 1999-06-29 | 2012-05-21 | Mannkind Corp | Purification and stabilization of peptides and proteins in pharmaceutical agents |
US7305986B1 (en) | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
GB9917637D0 (en) * | 1999-07-27 | 1999-09-29 | Co Ordinated Drug Dev | Improvements in or relating to inhaler devices |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
CA2382821A1 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
GB9920839D0 (en) | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
EP1235605B1 (en) * | 1999-12-07 | 2005-06-01 | Orion Corporation | Multidose powder inhaler |
PL204106B1 (en) | 2000-02-28 | 2009-12-31 | Pharmakodex Ltd | Improvements in or relating to the delivery of oral drugs |
AU6124601A (en) * | 2000-05-10 | 2001-11-20 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US20030003057A1 (en) * | 2000-07-07 | 2003-01-02 | Jeffry Weers | Methods for administering leuprolide by inhalation |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
CN1294142C (en) | 2000-08-05 | 2007-01-10 | 葛兰素集团有限公司 | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
DE10040528A1 (en) * | 2000-08-18 | 2002-02-28 | Pari Gmbh | Inhalation device and method for generating a particle mist for inhalation purposes |
DE10047722A1 (en) * | 2000-09-27 | 2002-04-11 | Schuckmann Alfred Von | Dosing device that can be activated by the user's suction air flow |
FI20002363A0 (en) * | 2000-10-27 | 2000-10-27 | Orion Yhtymae Oyj | powder inhaler |
JP2005504715A (en) | 2000-12-29 | 2005-02-17 | アドバンスト インハレーション リサーチ,インコーポレイテッド | Inhalable particles with sustained release characteristics |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
CA2435982C (en) * | 2001-02-06 | 2014-05-06 | Innovata Biomed Limited | Medicaments |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
WO2002076933A1 (en) | 2001-03-22 | 2002-10-03 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
JP4371660B2 (en) * | 2001-04-26 | 2009-11-25 | ニユー・イングランド・フアーマシユーテイカルズ・インコーポレイテツド | Metered dose devices for liquid and powdered drugs |
ATE411334T1 (en) | 2001-04-30 | 2008-10-15 | Glaxo Group Ltd | ANTIPHLOGISTIC 7.BETA.-CARBOTHIOATE ESTER DERIVATIVES OF ANDROSTAN WITH A 17.ALPHA.-CYCLIC ESTER GROUP |
FI20011317A0 (en) * | 2001-06-20 | 2001-06-20 | Orion Corp | The powder inhaler |
US6681768B2 (en) | 2001-06-22 | 2004-01-27 | Sofotec Gmbh & Co. Kg | Powder formulation disintegrating system and method for dry powder inhalers |
DE10129703A1 (en) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Atomizing system for a powder mixture and method for dry powder inhalers |
HU228508B1 (en) | 2001-09-14 | 2013-03-28 | Glaxo Group Ltd | Phenethanolamine derivatives and pharmaceutical composition containing them |
JP3619176B2 (en) * | 2001-09-14 | 2005-02-09 | オムロンヘルスケア株式会社 | Aerosol particle sorting device and inhaler |
AU2002333644A1 (en) | 2001-09-17 | 2003-04-01 | Glaxo Group Limited | Dry powder medicament formulations |
WO2003043603A1 (en) * | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Particulate compositions for improving solubility of poorly soluble agents |
PT1455755E (en) * | 2001-11-20 | 2013-06-18 | Civitas Therapeutics Inc | Improved particulate compositions for pulmonary delivery |
GB0128148D0 (en) * | 2001-11-23 | 2002-01-16 | Innovata Biomed Ltd | Assembly |
SI1458360T1 (en) | 2001-12-19 | 2011-08-31 | Novartis Ag | Pulmonary delivery of aminoglycosides |
ES2300568T3 (en) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | INHALATION APPARATUS |
UA80123C2 (en) * | 2002-04-09 | 2007-08-27 | Boehringer Ingelheim Pharma | Inhalation kit comprising inhalable powder of tiotropium |
US20030235538A1 (en) | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
SE524957C2 (en) | 2002-04-12 | 2004-11-02 | Microdrug Ag | Method for dividing and distributing in air of dry powder drug |
SE525027C2 (en) | 2002-04-12 | 2004-11-16 | Microdrug Ag | Device comprising a powder air grinder |
US20030196661A1 (en) * | 2002-04-19 | 2003-10-23 | Miekka Richard George | Power inhaler employing unit doses of powders in pressurized packages |
ES2298511T3 (en) | 2002-04-25 | 2008-05-16 | Glaxo Group Limited | DERIVATIVES OF PHENETHANOLAMINE. |
US6941980B2 (en) * | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
DE10300032B3 (en) * | 2003-01-03 | 2004-05-27 | E. Braun Gmbh | Inhaler for powdered medicament has pivoted inhalation tube which shuts off powder supply when in out-of-use position, and doses powder into airflow when in use |
US20040173211A1 (en) * | 2003-01-14 | 2004-09-09 | Boehringer Ingelheim International Gmbh | Powder inhaler |
EP1587482A4 (en) * | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | Anti-inflammatory compositions and uses thereof |
PE20040950A1 (en) | 2003-02-14 | 2005-01-01 | Theravance Inc | BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
DE10317461A1 (en) | 2003-04-16 | 2004-10-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt |
EP1624866A2 (en) * | 2003-05-16 | 2006-02-15 | Arriva Pharmaceuticals, Inc. | Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors |
TW200510298A (en) | 2003-06-13 | 2005-03-16 | Theravance Inc | Substituted pyrrolidine and related compounds |
GB0315509D0 (en) | 2003-07-02 | 2003-08-06 | Meridica Ltd | Dispensing device |
TW200519108A (en) | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
FI20031158A (en) * | 2003-08-15 | 2005-02-16 | Perlos Oyj | Inhalator |
EP1663159A4 (en) * | 2003-09-10 | 2010-06-09 | Map Pharmaceuticals Inc | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
SE0302665D0 (en) * | 2003-10-07 | 2003-10-07 | Astrazeneca Ab | Novel Process |
JP2007508390A (en) | 2003-10-14 | 2007-04-05 | グラクソ グループ リミテッド | Muscarinic acetylcholine receptor antagonist |
WO2005037224A2 (en) | 2003-10-17 | 2005-04-28 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
WO2005041848A2 (en) * | 2003-10-27 | 2005-05-12 | Oriel Therapeutics, Inc. | Dry powder drug containment system packages with tabs, inhalers and associated methods |
PE20050489A1 (en) | 2003-11-04 | 2005-09-02 | Glaxo Group Ltd | ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS |
EP1691782A1 (en) * | 2003-12-03 | 2006-08-23 | Microdrug AG | Medical product containing tiotropium |
SE0303270L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Method of administration of tiotropium |
SE0303570L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Moisture-sensitive medical product |
GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
WO2005095407A1 (en) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
BRPI0509382A (en) | 2004-04-02 | 2007-09-18 | Glaxo Group Ltd | process for the preparation of a compound monohydrochloride salt, crystalline monohydrochloride, process for obtaining crystalline monohydrochloride, method for the prophylaxis or treatment of a clinical condition in a mammal, use of crystalline monohydrochloride, pharmaceutical formulation, and, combination |
US8851069B2 (en) * | 2004-04-21 | 2014-10-07 | Innovata Biomed Limited | Inhaler |
GB0409197D0 (en) | 2004-04-24 | 2004-05-26 | Innovata Biomed Ltd | Device |
AR050902A1 (en) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION |
WO2005112644A2 (en) | 2004-05-13 | 2005-12-01 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
ES2257152B1 (en) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS. |
NZ551669A (en) | 2004-05-31 | 2010-07-30 | Almirall Lab | Combinations comprising antimuscarinic agents and PDE4 inhibitors |
US20060120972A1 (en) * | 2004-11-09 | 2006-06-08 | Peter Engels | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension |
NZ556709A (en) | 2005-02-10 | 2009-09-25 | Glaxo Group Ltd | Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
AR053450A1 (en) | 2005-03-25 | 2007-05-09 | Glaxo Group Ltd | DERIVATIVES OF 3,4-DIHYDRO-PYRIMID (4,5-D) PYRIMIDIN-2- (1H) -ONA 1,5,7 TRISUSTITUTED AS INHIBITORS OF QUINASE P38 |
AR053346A1 (en) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38 |
US7767691B2 (en) | 2005-08-18 | 2010-08-03 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system |
TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
GB2433207B (en) | 2006-02-21 | 2009-01-07 | Jianhe Li | Active suction actuated inhalers with timing devices |
CA2644679C (en) * | 2006-03-03 | 2013-12-03 | Stc.Unm | Dry powder inhaler with aeroelastic dispersion mechanism |
GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
EP1844805A1 (en) * | 2006-04-13 | 2007-10-17 | Boehringer Ingelheim Pharma GmbH & Co.KG | Inhaler |
PT103481B (en) * | 2006-05-16 | 2008-08-01 | Hovione Farmaciencia S A | INHALER OF SIMPLE USE AND INHALATION METHOD |
ES2306595B1 (en) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 . |
CA2677838C (en) | 2007-02-11 | 2017-08-01 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
ES2320955B1 (en) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF 3 - ((1,2,4) TRIAZOLO (4,3-A) PIRIDIN-7-IL) BENZAMIDA. |
AR065804A1 (en) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT |
WO2009046215A2 (en) * | 2007-10-02 | 2009-04-09 | Lab International Srl | Safety and abuse deterrent improved device |
JP5081771B2 (en) * | 2007-11-09 | 2012-11-28 | 日立オートモティブシステムズ株式会社 | Powder drug dispenser |
ES2320961B1 (en) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) PHENOL AS BETA2 ADRENERGIC RECEIVER AGONISTS. |
EP2096105A1 (en) | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
DK2548456T3 (en) | 2008-03-20 | 2015-09-28 | Virun Inc | Emulsions including (comprising) a PEG derivative of tocopherol |
MX2010010214A (en) * | 2008-03-20 | 2010-12-21 | Virun Inc | Vitamin e derivatives and their uses. |
SG192447A1 (en) * | 2008-03-27 | 2013-08-30 | Mannkind Corp | A dry powder inhalation system |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
WO2010008475A2 (en) * | 2008-06-23 | 2010-01-21 | Virun, Inc. | Compositions containing nono-polar compounds |
TWI532497B (en) | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
UY32297A (en) | 2008-12-22 | 2010-05-31 | Almirall Sa | MESILATE SALT OF 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLITOXI) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONA AS A RECEIVER AGONIST B (BETA ) 2 ACRENERGIC |
WO2010091198A1 (en) * | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
PL2400950T3 (en) | 2009-02-26 | 2019-12-31 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
MY186975A (en) | 2009-06-12 | 2021-08-26 | Mannkind Corp | Diketopiperazine microparticles with defined specific surface areas |
AU2010260177A1 (en) | 2009-06-16 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof |
CN102470130B (en) | 2009-07-15 | 2013-09-04 | 施万制药 | Crystalline freebase forms of a biphenyl compound |
EP2477642A4 (en) * | 2009-09-17 | 2013-03-13 | Mutual Pharmaceutical Co | Method of treating asthma with antiviral agents |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
EP2498848A2 (en) | 2009-11-12 | 2012-09-19 | Stc.Unm | Dry powder inhaler with flutter dispersion member |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
CN104744215B (en) | 2010-03-03 | 2019-03-15 | 尼昂克技术公司 | Pharmaceutical compositions containing monoterpenes |
WO2011119228A1 (en) | 2010-03-23 | 2011-09-29 | Virun, Inc. | Nanoemulsion including sucrose fatty acid ester |
EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
WO2012026963A2 (en) | 2010-08-23 | 2012-03-01 | Darren Rubin | Systems and methods of aerosol delivery with airflow regulation |
US9757528B2 (en) | 2010-08-23 | 2017-09-12 | Darren Rubin | Nebulizer having different negative pressure threshold settings |
BR112013004698B1 (en) | 2010-08-27 | 2022-03-22 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
ES2845185T3 (en) | 2010-08-31 | 2021-07-26 | Glaxosmithkline Ip Dev Ltd | Pharmacological products for the inhalation of dry powder that have humidity control properties and procedures for their administration |
AU2011298315B2 (en) | 2010-08-31 | 2014-08-28 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
SG190793A1 (en) | 2010-11-11 | 2013-07-31 | Agency Science Tech & Res | Targeting metabolic enzymes in human cancer |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
JP6050758B2 (en) | 2010-12-07 | 2016-12-21 | レスピラ セラピューティクス インコーポレイテッドRespira Therapeutics,Inc. | Dry powder inhaler and method of operating the same |
EP3130579B1 (en) | 2010-12-17 | 2024-02-07 | University of Southern California | Conjugates of isoperillyl alcohol |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
AU2012236150B2 (en) | 2011-04-01 | 2016-03-31 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
AU2012337241B2 (en) | 2011-12-30 | 2016-10-13 | Grifols, S.A. | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations |
EP2811847B1 (en) | 2012-02-10 | 2017-12-13 | Virun, Inc. | Beverage compositions containing non-polar compounds |
US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
AR090847A1 (en) | 2012-04-27 | 2014-12-10 | Glaxo Group Ltd | MODULATING COMPOUNDS OF THE ORPHAN RETINOID RECEIVER (ROR) |
GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
EP2668941A1 (en) | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
RU2650035C2 (en) | 2012-07-12 | 2018-04-06 | Маннкайнд Корпорейшн | Dry powder drug delivery systems and methods |
AU2013290616B2 (en) | 2012-07-19 | 2016-03-10 | Adamis Pharmaceuticals Corporation | Powder feeding apparatus |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
EP2925328A1 (en) | 2012-11-28 | 2015-10-07 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
KR20150096732A (en) | 2012-12-18 | 2015-08-25 | 알미랄, 에스.에이. | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity |
TW201446767A (en) | 2013-02-15 | 2014-12-16 | Almirall Sa | Pyrrolotriazine derivatives as PI3K inhibitors |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
KR102246914B1 (en) | 2013-03-15 | 2021-04-30 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
CA2918369C (en) | 2013-07-18 | 2021-06-29 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US9693574B2 (en) | 2013-08-08 | 2017-07-04 | Virun, Inc. | Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch |
WO2015091285A1 (en) | 2013-12-19 | 2015-06-25 | Almirall S.A. | Dosage formulation comprising salmeterol and fluticasone propionate |
EP3107606B1 (en) | 2014-02-21 | 2024-08-28 | David Brown | Inhalation device for inhaling powders |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
US10016363B2 (en) | 2014-09-18 | 2018-07-10 | Virun, Inc. | Pre-spray emulsions and powders containing non-polar compounds |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
MX2017009112A (en) | 2015-01-14 | 2018-06-15 | Respira Therapeutics Inc | Powder dispersion methods and devices. |
CN107613768B (en) | 2015-02-12 | 2020-10-20 | NeOnc技术股份有限公司 | Pharmaceutical composition comprising perillyl alcohol derivatives |
CN107428828A (en) | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | TSLP associated proteins |
MA41938A (en) | 2015-04-21 | 2018-02-28 | Almirall Sa | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES USED AS SODIUM CHANNEL INHIBITORS |
WO2016180753A1 (en) * | 2015-05-08 | 2016-11-17 | Iconovo Ab | Dry powder inhaler |
SI3782996T1 (en) | 2015-06-15 | 2024-06-28 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
MA52032A (en) | 2015-06-15 | 2021-01-20 | Astex Therapeutics Ltd | NRF2 REGULATORS |
EP3307719A1 (en) | 2015-06-15 | 2018-04-18 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
WO2016202800A1 (en) | 2015-06-16 | 2016-12-22 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
TW201722965A (en) | 2015-08-16 | 2017-07-01 | 葛蘭素史密斯克藍智慧財產發展有限公司 | Compounds for use in antibacterial applications |
EP3371167A1 (en) | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
WO2017076990A1 (en) | 2015-11-05 | 2017-05-11 | Almirall, S.A. | Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide |
TW201825458A (en) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產(第二)有限公司 | TRPV 4 antagonists |
AU2017330620A1 (en) | 2016-09-20 | 2019-03-28 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonists |
JP7144411B2 (en) | 2016-11-30 | 2022-09-29 | ネオンク テクノロジーズ インク. | Perillyl alcohol-3-bromopyruvate conjugate and cancer treatment method |
WO2018104766A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
JP2020500919A (en) | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Pyrrole 3-carboxylate as NRF2 regulator |
WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
ES2978187T3 (en) | 2016-12-14 | 2024-09-06 | Glaxosmithkline Intellectual Property Dev | Bisaryl heterocycles as NRF2 activators |
ES2848699T3 (en) | 2016-12-14 | 2021-08-11 | Glaxosmithkline Ip Dev Ltd | 3-Oxo-1,4-diazepinyl compounds as activators of NRF2 |
JP2020502136A (en) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Bisarylamides as NRF2 regulators |
JP2020502152A (en) | 2016-12-15 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Ether-linked triazoles as NRF2 activators |
KR20190091455A (en) | 2016-12-15 | 2019-08-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | NRF2 Compound |
WO2018174938A1 (en) | 2017-03-23 | 2018-09-27 | Virun, Inc. | Stable dry powders and emulsions containing probiotics and mucoadhesive protein |
KR102598466B1 (en) | 2017-04-24 | 2023-11-03 | 코크리스탈 파마, 아이엔씨. | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
TW201919682A (en) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | Novel compounds activating the Nrf2 pathway |
WO2019066702A1 (en) | 2017-09-28 | 2019-04-04 | Iconovo Ab | A dry powder inhaler with means for enhancing dispersion |
EP3723764A1 (en) | 2017-12-11 | 2020-10-21 | GlaxoSmithKline Intellectual Property Development Ltd | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
GB201720989D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
TWI795510B (en) | 2018-01-17 | 2023-03-11 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | PI4KIIIβ INHIBITORS |
KR20200118084A (en) | 2018-02-08 | 2020-10-14 | 네온씨 테크놀로지스, 아이엔씨. | Methods of penetration of the blood brain barrier |
EP3796906A1 (en) | 2018-05-23 | 2021-03-31 | GlaxoSmithKline Intellectual Property Management Limited | Indanes as nrf2 activators |
KR20210038908A (en) | 2018-07-27 | 2021-04-08 | 코크리스탈 파마, 아이엔씨. | Pyrrolo[2,3-b]pyridine derivatives as inhibitors of influenza virus replication |
TWI844564B (en) | 2018-09-10 | 2024-06-11 | 美商共結晶製藥公司 | Inhibitors of influenza virus replication |
KR102620705B1 (en) | 2018-10-11 | 2024-01-04 | 삼성전자주식회사 | Electronic device and operating method thereof |
WO2020081751A1 (en) | 2018-10-17 | 2020-04-23 | Cocrystal Pharma, Inc. | Combinations of inhibitors of influenza virus replication |
KR20210091753A (en) | 2018-11-13 | 2021-07-22 | 코크리스탈 파마, 아이엔씨. | Influenza treatment formulation |
WO2020112716A1 (en) | 2018-11-26 | 2020-06-04 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
CA3123725A1 (en) * | 2019-02-15 | 2020-08-20 | Iconovo Ab | Inhaler |
EP3937957A1 (en) | 2019-03-14 | 2022-01-19 | OM Pharma SA | Process for making stable bacterial extracts and their use as pharmaceuticals |
CA3132082A1 (en) | 2019-03-14 | 2020-09-17 | Om Pharma Sa | Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders |
GB201908536D0 (en) | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
US20230151034A1 (en) | 2020-03-17 | 2023-05-18 | Cocrystal Pharma, Inc. | Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication |
CN115698035A (en) | 2020-04-10 | 2023-02-03 | 共晶制药公司 | Inhibitors of norovirus and coronavirus replication |
EP4138884A1 (en) | 2020-04-20 | 2023-03-01 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
WO2022179967A1 (en) | 2021-02-23 | 2022-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Vadadustat for treating covid-19 in a hospitalized subject |
WO2023014758A1 (en) | 2021-08-03 | 2023-02-09 | Cocrystal Pharma, Inc. | Inhibitors for coronaviruses |
WO2023205389A1 (en) | 2022-04-22 | 2023-10-26 | Quench Medical Inc. | Dry powder inhalation delivery of pharmaceuticals |
WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11485A (en) * | 1854-08-08 | Befbigeeatob fobj maeine ejstgiites | ||
US2641254A (en) * | 1948-10-18 | 1953-06-09 | Frederick M Turnbull | Applicator |
US2587215A (en) * | 1949-04-27 | 1952-02-26 | Frank P Priestly | Inhalator |
US2573918A (en) * | 1949-11-05 | 1951-11-06 | Vick Chemical Company | Device for dispensing medicaments |
US2581182A (en) * | 1950-03-14 | 1952-01-01 | Abbott Lab | Inhaler |
DE1813993C3 (en) * | 1968-12-11 | 1974-01-24 | Paul Ritzau Pari-Werk Kg, 8135 Soecking | Device for atomizing and atomizing liquid or powdery substances |
US3653380A (en) * | 1970-02-16 | 1972-04-04 | American Cyanamid Co | Aerosol powder dosage dispensing device |
US4003500A (en) * | 1970-12-31 | 1977-01-18 | Hoechst Aktiengesellschaft | Metering device |
US3831606A (en) * | 1971-02-19 | 1974-08-27 | Alza Corp | Auto inhaler |
DE2502251A1 (en) * | 1975-01-17 | 1976-07-22 | Schering Ag | DEVICE FOR INHALATION OF POWDERED SOLIDS |
SU651766A1 (en) * | 1975-11-25 | 1979-03-15 | Литовский Научно-Исследовательский Институт Ветеринарии | Electric aerosol apparatus for animal vaccination |
SU570775A1 (en) * | 1976-02-02 | 1977-08-30 | Институт Теоретических Проблем Химической Технологии Ан Азербайджанской Сср | Volumetric micrometering device |
GB1562732A (en) * | 1976-02-10 | 1980-03-12 | Allen & Hanburys Ltd | Device for dispensing medicaments |
DE2716323C2 (en) * | 1977-04-07 | 1986-03-13 | Schering AG, 1000 Berlin und 4709 Bergkamen | Device for inhalation of medicaments |
DE2807866C2 (en) * | 1978-02-23 | 1979-09-20 | Plasmainvent Ag, Zug (Schweiz) | Device for the metered supply of powder to a powder processing unit |
DE2837040C2 (en) * | 1978-08-24 | 1982-10-21 | Siemens AG, 1000 Berlin und 8000 München | Liquid transport system for an inhalation device |
SU799766A1 (en) * | 1979-01-18 | 1981-01-30 | Московский Научно-Исследовательс-Кий Институт Вакцин И Сывороток Им.И.И.Мечникова | Device for spraying powder-like substances |
IT7920688V0 (en) * | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | INHALER FOR PULVERULENT MEDICINAL SUBSTANCES, WITH COMBINED DOSER FUNCTION. |
US4253591A (en) * | 1979-06-18 | 1981-03-03 | General Electric Company | Mercury doser |
US4262666A (en) * | 1979-10-24 | 1981-04-21 | Nelson Byron G | Inhalator-breathing apparatus |
-
1982
- 1982-06-10 AT AT82850129T patent/ATE23272T1/en not_active IP Right Cessation
- 1982-06-10 EP EP82850129A patent/EP0069715B1/en not_active Expired
- 1982-06-10 DE DE8282850129T patent/DE3274065D1/en not_active Expired
- 1982-06-10 CY CY1492A patent/CY1492A/en unknown
- 1982-06-14 IL IL66053A patent/IL66053A/en not_active IP Right Cessation
- 1982-06-15 IS IS2734A patent/IS1268B6/en unknown
- 1982-06-16 ZA ZA824264A patent/ZA824264B/en unknown
- 1982-06-17 IN IN456/DEL/82A patent/IN158972B/en unknown
- 1982-06-17 US US06/389,213 patent/US4524769A/en not_active Expired - Lifetime
- 1982-06-17 CA CA000405376A patent/CA1178151A/en not_active Expired
- 1982-06-21 PH PH27463A patent/PH22387A/en unknown
- 1982-06-23 IE IE1495/82A patent/IE53933B1/en not_active IP Right Cessation
- 1982-06-29 YU YU1414/82A patent/YU45115B/en unknown
- 1982-07-05 AU AU85608/82A patent/AU559297B2/en not_active Expired
- 1982-07-05 NZ NZ201154A patent/NZ201154A/en unknown
- 1982-07-07 DK DK304482A patent/DK159052C/en not_active IP Right Cessation
- 1982-07-07 PT PT75211A patent/PT75211B/en unknown
- 1982-07-07 JP JP57117050A patent/JPS5819269A/en active Granted
- 1982-07-07 ES ES1982276079U patent/ES276079Y/en not_active Expired
- 1982-07-07 FI FI822423A patent/FI77375C/en not_active IP Right Cessation
- 1982-07-07 NO NO822370A patent/NO154294C/en not_active IP Right Cessation
- 1982-07-07 HU HU822219A patent/HU189154B/en unknown
- 1982-07-07 GR GR68677A patent/GR76522B/el unknown
- 1982-07-08 PL PL1982237363A patent/PL132252B1/en unknown
- 1982-07-08 KR KR8203041A patent/KR880001811B1/en active
- 1982-07-10 EG EG419/82A patent/EG16516A/en active
-
1987
- 1987-10-01 MY MYPI87002747A patent/MY100090A/en unknown
-
1989
- 1989-06-12 SG SG370/89A patent/SG37089G/en unknown
- 1989-06-21 KE KE3890A patent/KE3890A/en unknown
- 1989-08-10 HK HK643/89A patent/HK64389A/en not_active IP Right Cessation
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4319514C2 (en) * | 1993-06-14 | 2003-06-18 | Sofotec Gmbh & Co Kg | powder inhaler |
DE4319514A1 (en) * | 1993-06-14 | 1994-12-15 | Asta Medica Ag | Bulk inhaler |
US5983893A (en) * | 1994-12-21 | 1999-11-16 | Astra Aktiebolag | Inhalation device |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US8513279B2 (en) | 1999-07-14 | 2013-08-20 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9056100B2 (en) | 1999-07-14 | 2015-06-16 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9333195B2 (en) | 1999-07-14 | 2016-05-10 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US8802699B2 (en) | 1999-07-14 | 2014-08-12 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US7125566B2 (en) | 1999-12-21 | 2006-10-24 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
US8933023B2 (en) | 2004-03-12 | 2015-01-13 | Biodel Inc. | Rapid acting injectable insulin compositions |
US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US7964615B2 (en) | 2005-05-20 | 2011-06-21 | Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor |
US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US7718609B2 (en) | 2006-04-12 | 2010-05-18 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US9254262B2 (en) | 2008-03-13 | 2016-02-09 | Almirall, S.A. | Dosage and formulation |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0069715B1 (en) | Powder inhalator | |
US4534345A (en) | Dosage inhalator | |
RU2100035C1 (en) | Inhaler | |
US6810874B1 (en) | Powder inhaler for combined medicament | |
US5823182A (en) | Medicament carrier for dry powder inhalator | |
US6435176B1 (en) | Spacer for use with a metered dose inhaler | |
IE41604B1 (en) | A device for the inhalation of medicaments | |
HU216405B (en) | Dry powder inhalator medicament carrier | |
PL196812B1 (en) | Powder inhaler for connected medicine | |
FI79947C (en) | Perforated diaphragm for use as a measuring and transporting means for a dosing respirator | |
NO157205B (en) | USE OF A PERFORED DISC AS A DOSING AND HOLDING DEVICE FOR FIXED, UNDINFORCED PHARMACOLOGICAL ACTIVE SUBSTANCE IN MICRONIZED FORM IN A DOSE INHALATOR. | |
JPH05505544A (en) | Device for measuring the dose of powdered drugs for inhalation | |
SI8211414A8 (en) | Inhalator with dosing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19821213 |
|
ITF | It: translation for a ep patent filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 23272 Country of ref document: AT Date of ref document: 19861115 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3274065 Country of ref document: DE Date of ref document: 19861211 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
EPTA | Lu: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 82850129.6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20010319 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20010327 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20010405 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20010502 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20010503 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20010531 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20010627 Year of fee payment: 20 Ref country code: CH Payment date: 20010627 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20010713 Year of fee payment: 20 |
|
BE20 | Be: patent expired |
Free format text: 20020610 A.B. *DRACO |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20020609 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20020609 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20020609 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20020610 Ref country code: LU Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20020610 Ref country code: AT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20020610 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed |
Ref document number: 82850129.6 |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20020610 |